2026-10-12T15:51:23Z https://www.scidb.cn/oai

10.57760/sciencedb.010ko 2026-08-28T10:26:46Z

2026-08-28 Vitamin A-blended nanostructured lipid carriers coated by chitosan orally delivering pirfenidone to treat liver fibrosis doi:10.57760/sciencedb.010ko en The prepared CV-NLC-PFD displayed a uniformly dispersed spherical morphology with a positive surface charge, exhibited noticeable sustained‑release behavior, and remained stable under simulated gastric and intestinal pH conditions. CV-NLC-PFD prolonged the T₁/₂ and MRT, and elevated the AUC, thereby extending the systemic circulation time and enhancing the oral bioavailability of PFD. CV‑NLC‑PFD also improved intestinal drug absorption and hepatic accumulation, demonstrating superior liver‑targeting capability. In In vivo pharmacodynamic studies, CV‑NLC‑PFD showed favorable anti‑fibrotic efficacy, as evidenced by marked suppression of HSCs activation and collagen deposition. These findings indicate that CV‑NLC‑PFD represents a promising nanocarrier for future liver fibrosis therapy. VA; Chitosan; pirfenidone 黄敏洁 RESTRICTED dataset Science Data Bank